Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot - A Pilot Study
Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot - A Pilot Study
This study is part of a research project for a University MD Program. This is an
 observational study aimed at comparing the differences in bone metabolism and
 microcirculation in patients with type 2 diabetes mellitus (with and without diabetic
 neuropathy and Charcot foot) with healthy subjects.

 Diabetes is gradually becoming a global epidemic along with its associated complications.
 Diabetes can affect several systems in our body particularly the eyes, nerves and the
 kidneys. The damaging effects occur at the level of the small blood vessels
 (microcirculation) that supply these vital structures. Normally, the inner lining of these
 blood vessels (endothelium) plays a very important role in maintaining adequate blood flow.
 The endothelium releases a chemical substance called nitric oxide, which relaxes these small
 blood vessels thereby ensuring sufficient blood supply to these key structures. Nitric oxide
 also prevents blockage of these vessels. Any form of metabolic stress like hyperglycaemia
 (raised blood sugar as seen in diabetes) can cause abnormal changes in the normal behaviour
 of the endothelium (endothelial dysfunction). Therefore hyperglycaemia promotes endothelial
 dysfunction by lowering nitric oxide levels, which may lead to diabetic complications like
 diabetic retinopathy (eye damage), nephropathy (kidney damage) or neuropathy (nerve damage).

 In addition, patients with diabetes also suffer from osteoporosis (thinning of bones).
 Osteoporosis is a bone disorder characterised by a reduction in bone mineral content leading
 to an increased risk of developing fractures. The increased risk of fractures in patients
 with type 2 diabetes is attributed to poor bone quality resulting from the harmful effects of
 high blood glucose. Studies have also shown that nitric oxide has a bone protective effect as
 demonstrated by its ability to prevent bone fragmentation and improve bone strength.

 Study of markers of endothelial function and bone metabolism will facilitate a better
 understanding about the origin of diabetic complications. This will aid in the development of
 novel therapeutic agents that target the harmful triggers in diabetes and eventually may
 prevent and retard the onset of the debilitating diabetic complications.
This is an observational study aimed at observing and comparing differences in bone
 metabolism and microcirculation in patients with type 2 diabetes and healthy controls.

 In this study, 50 participants will be recruited and then categorised into the following
 groups:

 1. Control group: 10 healthy volunteers (Hospital staff and spouses/ partners of patients
 will volunteer as healthy subjects)

 2. Type 2 diabetic patients without neuropathy: 10

 3. Type 2 diabetic patients with neuropathy:

 -  10 patients with painless neuropathy

 -  10 patients with painful neuropathy

 4. Type 2 diabetic patients with unilateral Charcot foot: 10

 Visit Schedule The estimated time for enrollment of patients will be within 3 months. The
 duration of the study is 5 months.

 Screening (-2 Weeks): To assess for eligibility. This will include informed consent process,
 medical history and physical examination, screening for neuropathy and routine bloods.
 Laboratory work-up done at screening will be considered for data analysis.

 Visit 1 - Baseline visit

 -  Anthropometric measures: Height, weight, BMI, waist circumference

 -  Vital parameters: supine and standing blood pressure, pulse, respiratory rate and
 temperature

 -  Laboratory assessment that includes markers of endothelial activation, inflammation and
 bone metabolism.

 -  Markers of endothelial activation will be investigated using systemic protein
 suspension array technology. For e.g. adhesion molecules like ICAM, VCAM and
 inflammatory molecules.

 -  Nitric oxide will be analysed using Griess assay

 -  Bone turnover markers [e.g., P1NP (Procollagen type 1 amino terminal propeptide),
 CTX (C-terminal cross-linked telopeptide of type-I collagen), Sclerostin, RANKL
 (receptor activator for nuclear factor (NF)-kB (RANK) ligand), OPG
 (osteoprotegerin), OPN (osteopontin), OCN (osteocalcin), BMP4 (Bone morphogenetic
 protein 4) and TGF-1β(Transforming growth factor-1β) - using ELISA (enzyme-linked
 immunosorbent assay).

 -  IL-6 - Interleukin-6, an inflammatory cytokine implicated in osteoporosis (using
 ELISA)

 -  Assessment of skin microcirculation with Laser Doppler Iontophoresis

 -  Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)

 -  Advanced glycation end-products will be assessed by an AGE reader which uses the
 technique of skin autofluorescence

 Clinical Procedures

 Assessment of the microcirculation with Laser Doppler Iontophoresis:

 A standard measurement of microcirculation is laser Doppler iontophoresis, which is used by
 several research institutes. In this trial the skin microcirculation will be measured on the
 dorsum of the foot using a Perimed Laser Doppler imager and iontophoresis system.

 Endothelial-mediated vasodilation will be measured by the iontophoresis of acetylcholine,
 while sodium nitroprusside will be used to measure endothelium-independent vasodilation. The
 iontophoresis system consists of an ION chamber (iontophoresis delivery vehicle device) that
 sticks firmly to the skin and a reference electrode. The response in blood flow will be
 imaged and quantified using the Perimed Laser Doppler Imager (PeriScan PIMII; Perimed,
 Sweden).

 Analysis of AGE:

 An AGE reader, which utilizes the principle of skin autofluorescence, will measure the
 accumulation of AGE in the skin. This validated device provides a real-time, non-invasive
 assessment of cardiovascular risk for chronic diseases like Diabetes, renal failure,
 cardiovascular disease, etc. AGE-modified proteins have autofluorescent properties and when
 excited by ultraviolet (UV) light they emit fluorescence in particular wavelengths. The
 levels of AGE in skin correlate with AGE levels in blood.

 The volar aspect of the forearm will be placed on the AGE reader, which is equipped with a UV
 light source. The UV light triggers AGE in skin, after penetrating 1mm of the dermis, to emit
 autofluorescence that is then detected by the AGE reader. The intensity of fluorescence
 correlates with the quantity of AGE in the skin.

 Assessment of calcaneal BMD:

 This is a simple and convenient method to assess peripheral BMD and assess fracture risk. The
 device used is a quantitative ultrasound called Sahara Clinical Bone Sonometer (Sahara
 Clinical Bone Sonometer; Hologic, Waltham, MA). The calcaneus is the preferred peripheral
 site to assess fracture risk. This device uses ultrasound waves to determine the BMD of the
 calcaneus. In this procedure, once the bare heel is placed in the device, the BMD is
 calculated within 30 seconds and the results are then generated on paper by the device.
Inclusion Criteria:

 -  • Subjects aged between 40-75 years

 -  Healthy subjects or non-diabetic subjects for the control group.

 -  A diagnosis of type 2 DM based on one of the following criteria (ADA - 2010):

 -  Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) or

 -  2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/L) during an OGTT or

 -  Classic symptoms of hyperglycaemia or hyperglycaemic crisis with a random plasma
 glucose ≥ 200 mg/dL (11.1 mmol/L).

 -  Patients on treatment for type 2 diabetes mellitus

 -  Presence of diabetic neuropathy will be confirmed when 2 of the following
 neurological tests are positive on examination (vibration perception threshold,
 10 gm. monofilament, 128 Hz tuning fork, ankle reflex, pin-prick)

 -  Painful diabetic neuropathy diagnosed according to LANSS (Leeds Assessment of
 Neuropathic Symptoms and Signs) scoring

 -  For patients with chronic Charcot foot, the diagnosis should be confirmed by
 clinical judgment and by radiologic examination - X-ray, technetium-labeled
 bisphosphonate bone scan or MRI)

 Exclusion Criteria:

 -  • At screening, age below 40 years and above 75 years.

 -  Type 1 diabetes mellitus (patients with a history of ketoacidosis, age of onset
 of DM before 25 years of age, BMI <21 kg/m2 and use of insulin without a
 concomitant oral hypoglycemic agent)

 -  Major cardiovascular complications within 3 months prior to screening

 -  Recent history of smoking within the last 6 months

 -  Scars, tattoos or rashes over the forearm

 -  Recent or current oral steroid therapy or topical steroids applied to the forearm

 -  Patients with uncontrolled hypertension (systolic blood pressure [SBP] > 160/90
 mmHg) or hypotension (SBP ≤ 100 mm Hg or a diastolic BP of ≤60 mm Hg) at
 screening.

 -  History of general systemic illness including cardiac, hepatic or renal
 insufficiency

 -  Patients with renal insufficiency characterized by a creatinine clearance of less
 than 60 ml/min or a serum creatinine of more than 130 μmol/l

 -  Receiving treatment for inflammatory disease or malignancy

 -  Other non-diabetic causes of neuropathy

 -  History of chronic alcohol consumption

 -  History of metabolic bone disorders (Osteoporosis, Paget's disease, etc.) or
 treatment for bone disorders (past or current treatment for osteoporosis,
 bisphosphonate therapy within the last 3 years)

 -  History of malignancy

 -  History of active foot ulcers

 -  History of concomitant therapy that may interfere with bone metabolism e.g.
 glucocorticoids (within the last 3 months), hormone replacement therapy (in the
 last 12 months), SERM (selective oestrogen receptor modulator),
 thiazolidinedione, anticonvulsant use

 -  Receiving drugs that fluoresce (e.g., Doxorubicin, Daunomycin, Camptothecin,
 Protoporphyrin, Fluoroquinolones, Tetracycline, Hydroxychloroquine or Quinidine)

 -  History of photosensitivity reactions (e.g., sensitive to ultraviolet light, or
 taking medication known to cause photosensitivity

 -  Simultaneous participation in other clinical trials or involvement in another
 research trial involving an investigational product in the past 12 weeks.